Worth reading
70In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
170000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 12th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) issued through a third-party allotment
Who receives how much170,000Shares
Number of shares delivered during the month: 170,000 shares (new shares)
EVO FUND (issued on 8 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+2.60%Rate of increase
7,454,419 shares7,624,419Shares
Exercise ratio subject to exercise restrictions: 2.6%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Subject to provisions for adjustment of the exercise price. The exercise price during the subject month was ¥172–¥205. The lower adjustment limit is Not disclosed
Number of Stock Acquisition Rights
Total number issued: 60,000 rights. Unexercised as of the end of the month preceding the subject month: 53,900 rights; unexercised as of the end of the subject month: 52,200 rights
Procedures under the Corporate Code of Conduct
Compliance with the exercise restrictions under Article 434 of the Listing Regulations is stated. The exercise ratio subject to exercise restrictions is 2.6%
Most recent equity financing
Timing 8 December 2025 / Type New shares issued through a third-party allotment, the 12th Stock Acquisition Rights (with an exercise price adjustment provision), the 13th Stock Acquisition Rights, and the 1st unsecured ordinary bonds (private placement to a limited number of investors) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 12th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) issued through a third-party allotment |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 170,000 shares (new shares) |
| Intended allottee | EVO FUND (issued on 8 December 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 2.6% |
| Total number of issued shares | As of the end of the month preceding the subject month: 7,454,419 shares → As of the end of the subject month: 7,624,419 shares |
| Exercise price | Subject to provisions for adjustment of the exercise price. The exercise price during the subject month was ¥172–¥205. The lower adjustment limit is Not disclosed |
| Number of Stock Acquisition Rights | Total number issued: 60,000 rights. Unexercised as of the end of the month preceding the subject month: 53,900 rights; unexercised as of the end of the subject month: 52,200 rights |
| Procedures under the Corporate Code of Conduct | Compliance with the exercise restrictions under Article 434 of the Listing Regulations is stated. The exercise ratio subject to exercise restrictions is 2.6% |
| Most recent equity financing | Timing 8 December 2025 / Type New shares issued through a third-party allotment, the 12th Stock Acquisition Rights (with an exercise price adjustment provision), the 13th Stock Acquisition Rights, and the 1st unsecured ordinary bonds (private placement to a limited number of investors) / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a report on the monthly exercise status; no reason for the exercises is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.